Following assessment of information related to levothyroxine, antiepileptics interactions and adverse events related to pancreatitis and oxalate nephropathy associated with OTC orlistat (alli®), the CHMP recommended updating the product information to reflect that patients taking medicines such as levothyroxine and antiepileptic drugs or patients with kidney disease should consult a doctor before starting treatment and that oxalate nephropathy and pancreatitis have been reported in a number of patients taking this medicine. 

The CHMP and Glaxo Group Ltd have agreed on a Direct Healthcare Professional Communication concerning this updated information.